Evommune, Inc. (NYSE: EVMN) announced that Phase 2a trial data for its drug candidate EVO301 in moderate-to-severe atopic dermatitis will ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE